GWAAIS 2022 Academic Conference Series - March
Lecture will be focused on mast cell activation syndrome. This is a disease with multiple symptoms involving different organ systems which can be difficult to diagnose and challenging to manage and treat.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and Greater Washington Allergy, Asthma and Immunology Society (GWAAIS). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.”
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Allergists and Allied Health Providers
Upon completion of this activity, participants should be able to:
1. Diagnose mast cell activation syndrome.
2. Actively manage and treat mast cell activation syndrome.
3. Identify disorders associated with mast cell.
All identified conflicts of interest have been mitigated.
The individuals listed below disclose the following financial relationships:
Cem Akin, MD
Advisor: Novartis, Blue Print Medicines Researcher: Blueprint Medicines
The following have no relevant financial relationships to disclose:
Theodore Kim, MD
- 1.25 AMA PRA Category 1 Credit™
- 1.25 Attendance